Zhejiang Hisun Pharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Zhejiang Hisun Pharmaceutical has a total shareholder equity of CN¥8.5B and total debt of CN¥4.6B, which brings its debt-to-equity ratio to 54.6%. Its total assets and total liabilities are CN¥16.3B and CN¥7.8B respectively. Zhejiang Hisun Pharmaceutical's EBIT is CN¥273.6M making its interest coverage ratio -9.3. It has cash and short-term investments of CN¥1.5B.
Key information
54.6%
Debt to equity ratio
CN¥4.64b
Debt
| Interest coverage ratio | -9.3x |
| Cash | CN¥1.48b |
| Equity | CN¥8.50b |
| Total liabilities | CN¥7.76b |
| Total assets | CN¥16.26b |
Recent financial health updates
Recent updates
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business
Sep 26
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well
Apr 30Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel
Mar 29Financial Position Analysis
Short Term Liabilities: 600267's short term assets (CN¥5.8B) do not cover its short term liabilities (CN¥6.2B).
Long Term Liabilities: 600267's short term assets (CN¥5.8B) exceed its long term liabilities (CN¥1.5B).
Debt to Equity History and Analysis
Debt Level: 600267's net debt to equity ratio (37.1%) is considered satisfactory.
Reducing Debt: 600267's debt to equity ratio has reduced from 121.4% to 54.6% over the past 5 years.
Debt Coverage: 600267's debt is well covered by operating cash flow (35.3%).
Interest Coverage: 600267 earns more interest than it pays, so coverage of interest payments is not a concern.